Bone metastases in prostate cancer: A targeted approach

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 254-258

  Storey, Jonathan A ^a   Torti, Frank M ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Biologic therapy; Bone metastasis; Drug development; Prostate cancer

Indexed keywords

ABEGRIN; ATRASENTAN; BONE MORPHOGENETIC PROTEIN 6; DENOSUMAB; DOXORUBICIN; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEXIDRONAM SAMARIUM SM 153; MONOCLONAL ANTIBODY; NOGGIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RHENIUM 186; SAMARIUM 153; SMALL INTERFERING RNA; STRONTIUM 89; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE MATRIX; BONE METASTASIS; BONE REMODELING; CANCER CONTROL; CANCER GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; GENE SILENCING; HUMAN; MALIGNANT TRANSFORMATION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR GROWTH;

BONE NEOPLASMS; BONE RESORPTION; HUMANS; MALE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; PROSTATIC NEOPLASMS;

EID: 34247148563     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32805e8787     Document Type: Review

References (32)

1. Pentyala SN, Lee J, Hsieh K, et al. Prostate cancer: a comprehensive review. Med Oncol 2000; 17:85-105.
2. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin Oncol 1994; 21:630-656.
3. Cheville JC, Tindall D, Boelter C, et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002; 95:1028-1036.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev 2002; 2:584-593.
5. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers elevated at baseline. J Urol 2000; 164:1248-1253.
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
7. Putnam JB Jr, Roth JA, Wesley JN, et al. Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors. Ann Thorac Surg 1983; 36:516-523.
8. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; i:571-573.
9. Camps JL, Chang SM, Hsu TC, et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Sci USA 1990; 87:75-79.
10. Chung LWK. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003; 97:772-778.
11. Aziz H, Choi K, Sohn C, et al. Comparison of P32 and SHBI for bony metastases. Am J Clin Oncol 1986; 9:264-268.
12. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25:805-813.
13. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63:940-945.
14. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxethylidenediphosphate. J Clin Oncol 2003; 21:2869-2875.
15. Tu S, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001; 357:336-341.
16. Zheng DQ, Woodard AS, Fornaro M, et al. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999; 59:1655-1664.
17. Hall CL, Dai JL, van Golen KL, et al. Type I collagen receptor (α2b1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006; 66:8648-8654. Paper demonstrates a role for integrin-mediated adhesion to collagen in the formation of bone metastases in a mouse model.
18. Bisanz K, Yu J, Edlund M, et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibit the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005; 12:634-643.
19. Nelson JB. Endothelin receptor antagonists. World J Urol 2005; 23:19-27.
20. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944-949.
21. Dai J, Keller J, Zhang J, et al. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005; 65:8274-8285.
22. Haudenschild DR, Palmer SM, Moseley TA, et al. Bone morphogenetic protein (BMP)-6-signaling and BMP antagonist noggin in prostate cancer. Cancer Res 2004; 64:8276-8284.
23. Feeley BT, Krenek L, Liu N, et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer bone lesions. Bone 2006; 38:154-166. In this paper, the overexpression of a BMP-antagonist was shown to limit osteolytic bone lesions, whereas previous work had been conducted in osteoblastic lesions.
24. Charhon SA, Chapuy MC, Delvin EE, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983; 51:918-924.
25. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zolendronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
26. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2004; 23:8219-8224.
27. Simonet WS, Lace CR, Dunstan M, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
28. Kiefer JA, Vessella RL, Quinn JE, et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate xenograft. Clin Exp Metastasis 2004; 21:381-387.
29. Lin BL, Tarnowski J, Zhang J, et al. Bone metastatic LNCaP-derived C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001; 47:212-221.
30. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001; 57:611-616.
31. Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/ osteoclastogenesis inhibitory factor decrease human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003; 63:2096-3012.
32. Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor kappa B Fc diminishes prostate cancer progression in bone. Cancer Res 2003; 63:7883-7890.